Science 37 Named Finalist in Two Categories for the 2026 SCOPE Awards

MORRISVILLE, NC — January 7, 2026 — Science 37, the leader in expanding patient access to clinical trials, today announced it has been named a finalist for two prestigious SCOPE Awards: the Participant Engagement Award and the Site Innovation Award. This marks the first time that a single company has been named a finalist for two SCOPE Award categories in the same year.

Driving Engagement Through Community Pharmacies

Science 37 was recognized for the Participant Engagement Award for its “Pharm-to-Trial” partnership with RxE2. This decentralized vaccine trial model brings research to agricultural U.S. communities by utilizing local pharmacies as trusted access points. Supported by Science 37’s research-grade nurses and board-certified investigators, this "hub-and-spoke" model removes socioeconomic barriers and leverages local healthcare relationships to improve diversity and data quality.

Redefining the Clinical Trial Site

The nomination for the Site Innovation Award honors Science 37’s Direct-to-Patient Clinical Trial Site, which enables participation directly from patients’ homes. With nationwide reach supported by 50-state medical licensure, the site expands access beyond traditional site boundaries and accelerates enrollment for clinical trial sponsors.

“These nominations reflect our commitment to expanding patient access while delivering operational excellence,” said Tyler Van Horn, Chief Executive Officer of Science 37. “Being the first company recognized in two categories simultaneously is a testament to our team's dedication to making research more accessible and inclusive.”

Final judging will take place at the SCOPE Summit in Orlando, Florida, February 2–5, 2026.

About Science 37

Science 37 accelerates clinical research by expanding patient access to trials, leading to faster approvals and better health outcomes for all. Our solutions empower life sciences companies to reach diverse populations beyond traditional means of conducting clinical research. To learn more, visit www.science37.com or email science37@science37.com.

To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies.

Media Inquiries
Science 37
PR@science37.com

Science 37 Honored for Site Innovation in the 2025 Clinical Trials Arena Excellence Awards

Science 37 Receives 2025 Clinical Trials Arena Site Innovation Award for R&D Leadership

MORRISVILLE, NC — December 2, 2025 — Science 37, the leader in expanding patient access to clinical trials, today announced that it has been awarded the Research and Development – Site Innovation honor in the 2025 Clinical Trials Arena Excellence Awards. The recognition highlights Science 37’s leadership in advancing clinical research through its Direct-to-Patient Clinical Trial Site, one of the industry’s most innovative and data-driven site models.

Powered by GlobalData’s independent research, the Clinical Trials Arena Excellence Awards celebrate organizations driving meaningful progress across key areas, including R&D, Safety, Diversity, and Social Impact.

Science 37’s Direct-to-Patient Site operates as a single, nationwide, FDA-inspected site that enables sponsors to enroll and retain participants in all 50 states. By eliminating geographic barriers, the model improves access, enhances equity, and consistently delivers high-quality performance across complex therapeutic areas.

Examples of recent contributions to sponsor programs, including:

“Receiving the Site Innovation Award reflects the transformative impact of our Direct-to-Patient Site,” said Tyler Van Horn, CEO of Science 37. “By enabling participation directly from the patient’s home, we’re broadening access, supporting regulatory confidence, and helping sponsors bring life-changing therapies to patients faster.”

As the first and only FDA-inspected Direct-to-Patient Clinical Trial Site, Science 37 has completed multiple inspections on pivotal Phase 3 trials, all resulting in No Action Indicated (NAI) outcomes. The model continues to deliver strong performance in complex programs, driving top enrollment in pivotal studies and supporting faster recruitment.

Read more about Science 37’s recognition.

About GlobalData

GlobalData Plc (AIM: DATA) is a leading data, insights, and analytics platform that delivers trusted proprietary insights and tailored intelligence solutions for the world's largest industries. The company’s mission is to help clients decode the future, make better decisions, and reach more customers.

By combining proprietary data with human expertise and powerful AI, GlobalData provides next-generation intelligence through one connected platform.

For more information, visit https://www.globaldata.com.

About Science 37

Science 37 accelerates clinical research by expanding patient access to trials, leading to faster approvals and better health outcomes for all. Our solutions empower life sciences companies to reach diverse populations beyond traditional means of conducting clinical research. To learn more, visit www.science37.com or email science37@science37.com.

To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies.

Media Inquiries

Science 37
pr@science37.com

Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial 

MORRISVILLE, NC — October 8, 2025 — Science 37, a leader in enhancing patient access to clinical trials, today announced the successful completion of its third FDA inspection, further affirming the quality and compliance of its Direct-to-Patient Site for clinical research. The inspection concluded with a No Action Indicated (NAI) categorization recommendation by the inspector, with no objectionable conditions noted and no Form 483 issued.

The review centered on Science 37’s contribution in a registrational Phase 3 primary biliary cholangitis (PBC) study, in which the company played a significant role, enrolling 47% of the US study population. The FDA evaluated internal processes, technology platforms, data integrity, patient safety measures, protocol adherence, Principal Investigator oversight, and all associated documentation.

This marks Science 37’s third consecutive successful FDA inspection in less than two years. Previous inspections in March 2024 and April 2025 also resulted in NAI categorizations, with no Form 483s issued, validating the company’s ability to consistently deliver high-quality, regulatory-compliant research across multiple pivotal studies.

“Our team’s consistent track record not only validates the rigor of our model but also demonstrates how direct-to-patient research can expand reach, safeguard patient safety, and deliver data of the highest integrity,” said Dr. Debra Weinstein, Chief Medical Officer at Science 37. “Each FDA inspection underscores the strength of our Direct-to-Patient Site in upholding the highest regulatory standards and validates how we are advancing clinical research with a strong emphasis on quality and compliance.”

Science 37’s Direct-to-Patient Site extends clinical trial reach beyond the geographic limitations of traditional sites by enabling participation directly from patients’ homes. Leveraging nationwide recruitment and 50-state medical licensure, Science 37 provides a comprehensive range of site services, including investigator oversight, research-grade nursing, CRC support, and direct-to-patient logistics. The site facilitates faster enrollment, enhances trial accessibility, and consistently delivers high-quality data across studies of varying complexity.

Science 37 continues to partner with clinical research sponsors seeking to enhance trial accessibility and enrollment. For more information, visit www.science37.com.

About Science 37

Science 37 accelerates clinical research by expanding patient access to trials, leading to faster approvals and better health outcomes for all. Our solutions empower life sciences companies to reach diverse populations beyond traditional means of conducting clinical research. To learn more, visit www.science37.com or email science37@science37.com.

To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies.

Media Inquiries

Science 37
pr@science37.com

Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research

MORRISVILLE, NC — September 4, 2025 — Science 37, the leader in expanding patient access to clinical trials, and Catalent®, a global leader in enabling pharma, biotech, and consumer health partners to optimize product development and supply, announced a strategic partnership redefining how investigational medicinal products (IMPs) are delivered directly to patients’ homes for clinical research.

Through this collaboration, Catalent supports Science 37’s Direct-to-Patient Clinical Trial Site model by providing reliable, efficient shipping and logistics services for study medications, ensuring rapid and secure delivery of IMPs across geographies and enabling patients to participate in clinical research from the comfort of their homes, regardless of their location.

“Catalent’s expertise in direct-to-patient logistics is a key enabler of our mission to expand access to clinical trials,” said Tyler Van Horn, CEO at Science 37. “By removing geographic barriers, we’re not only reaching more diverse patient populations, we’re also driving faster enrollment and generating high-quality data that helps bring treatments to market sooner.”

Science 37 and Catalent have partnered to refine the IMP supply chain for at-home trial participation and visit execution. Across 17 studies, Catalent and Science 37's partnership enrolled nearly 1,700 patients by bringing clinical trials directly into the home, enrolling an average 26% of the total study population in a single Direct-to-Patient Site, with 9 patients enrolled per month or the equivalent of more than 15 brick-and-mortar locations in each instance. To date, the partnership has delivered over 6,400 shipments to study participants.

This integrated solution offers sponsors an end-to-end clinical trial site under a single contract and budget, streamlining operations, improving enrollment speed and retention rates, and expanding access to underserved and geographically dispersed populations.

“Our partnership with Science 37 transforms the clinical trial experience, bringing research directly to participants while preserving the rigor and efficiency on which sponsors rely,” said Ricky Hopson, President, Clinical and Specialty Services, and Chief of Staff at Catalent. “Together, we’re advancing a more inclusive and patient-centered future for clinical research, without compromising precision or quality.”

To learn more about how Science 37 and Catalent are transforming clinical research, visit www.science37.com and www.catalent.com.

About Catalent

Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and multi-modality manufacturing, Catalent supports the acceleration of development programs and the launch of more than a hundred new products every year. Powered by thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. 

For more information, visit www.catalent.com.

About Science 37

Science 37 accelerates clinical research by expanding patient access to trials, leading to faster approvals and better health outcomes for all. Our solutions empower life sciences companies to reach diverse populations beyond traditional means of conducting clinical research. To learn more, visit www.science37.com or email science37@science37.com.

To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies.

Media Inquiries

Science 37
pr@science37.com

Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial

MORRISVILLE, NC — April 8, 2025 — Science 37, a leader in enhancing patient access to clinical trials, today announced the successful completion of its second FDA inspection, reaffirming the quality of its Direct-to-Patient Site for clinical research. The inspection resulted in a No Action Indicated (NAI) categorization, with no objectionable conditions noted and no Form 483 issued.

Led by Science 37's internal Quality Assurance & Compliance team, the inspection focused on the company’s role in a registrational Phase 3 asthma study, which Science 37 contributed 28% of the total patient enrollment. The FDA evaluated internal processes, technology, data integrity, patient safety, protocol adherence, Principal Investigator oversight, and all associated documentation. This marks Science 37’s second successful FDA inspection within the last 13 months, following a similar review in March 2024 that assessed three pivotal Phase 3 trials.

“The results of this FDA inspection further validate the strength of our Direct-to-Patient Site in maintaining the highest regulatory standards while transforming clinical trial access,” said Irena Lambridis, VP and Head of Quality Assurance & Compliance at Science 37. “By expanding reach and ensuring rigorous oversight, we are helping sponsors accelerate timelines, optimize data integrity, and bring life-changing treatments to patients faster.”

“As an Investigator for Science 37, I have complete oversight of study visits through our telemedicine platform and close coordination with our research-grade nurses,” said Dr. Debra Weinstein, VP of Internal Medicine at Science 37. “Our Direct-to-Patient Site enables us to conduct comprehensive assessments and ensure protocol adherence remotely—delivering the quality and compliance validated by this FDA inspection.”

Science 37’s Direct-to-Patient Site empowers clinical trial sponsors to reach 100% of their target patient population by bringing research directly to patients’ homes. With nationwide reach, investigators with 50-state medical licensure, and research-grade nursing, the site enhances enrollment speed while delivering high-quality results.

Science 37 continues to partner with clinical research sponsors seeking to enhance trial accessibility and enrollment. For more information, visit www.science37.com.

About Science 37

Science 37 accelerates clinical research by expanding patient access to trials, leading to faster approvals and improved health outcomes. Our solutions empower life sciences companies to reach diverse populations beyond traditional research methods. Learn more at www.science37.com or contact science37@science37.com.

Media Inquiries

Science 37 | PR@science37.com

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

Seasoned Strategist and Former Chief Commercial Officer Poised to Accelerate Access and Equity in Clinical Research

MORRISVILLE, NC — January 14, 2025 — Science 37, a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company’s Chief Commercial Officer, Van Horn’s appointment follows his pivotal role in driving operational excellence and shaping the company’s strategic direction to better prioritize client success – initiatives credited with driving growth for the company.

Since joining Science 37 in 2021, Van Horn has been a chief architect in assembling and empowering a team capable of matching or surpassing the testing standards and data quality of traditional clinical trial sites. By emphasizing the well-being and safety of patients through the delivery of convenient, at-home services, Van Horn sees Science 37 solving the most acute patient enrollment and study conduct pain points facing its clinical research clients. 

“The future of clinical research lies in enabling therapies to reach their endpoints faster, gaining approval, and ensuring equitable, improved health outcomes for all,” said Van Horn. “As CEO, I am dedicated to supporting sponsors with our world-class research teams and innovative solutions. Our commitment to expanding patient access remains at the heart of everything we do, especially as we strive to reach underserved populations and drive meaningful change in healthcare.”

Van Horn’s elevation to CEO positions Science 37 to seamlessly build upon the learning of past successes. It also redoubles the company’s commitment to growth through purposeful innovation and enhanced solution delivery. By prioritizing the patient and study sponsors, Science 37 is leading the way, ushering in a new era of accessibility, diversity, and patient safety in clinical research. 

For more information about Science 37 and its unique approach to clinical research, visit www.science37.com.

About Science 37

Science 37 accelerates clinical research by expanding patient access to trials, leading to faster approvals and better health outcomes. Our Direct-to-Patient Site and Patient Recruitment solutions enable life sciences companies to reach beyond traditional means of conducting clinical research. To learn more, visit www.science37.com, or email science37@science37.com.

To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies. 

Media Inquiries

Science 37
pr@science37.com

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial

Science 37, a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical company, GSK. The hepatology study of an investigational medicine for cholestatic pruritus in primary biliary cholangitis (PBC) required 230 global participants, of which Science 37 was able to contribute almost half (17 - 47%) of the U.S. enrollment for the study.

Recognizing that the available participant population for rare disease studies is often extremely limited and dispersed globally, GSK welcomed an innovative approach to expanding trial access—one that would also help patients overcome symptom-based barriers such as fatigue that make it challenging to adhere to frequent site visits required in traditional clinical trials. Science 37's Direct-to-Participant Site solution allowed participants to take part in the study from home, reducing participant burden, especially if they lived far from traditional brick-and-mortar sites. By extending geographic access and facilitating real-time, at-home data collection, Science 37 significantly expanded the pool of qualified participants, a key factor to its U.S. enrollment contribution.

“At GSK, we design trials with a patient centric approach which leverages technology and remote services in order to make trials more accessible for participation. Science 37’s innovative services meant we could bring the trial to the homes or neighborhoods of patients in rural areas who would typically have to travel hundreds of miles to the nearest clinical site, which may otherwise have been a barrier to participating,” said Brandon Maggio, Global Head of Digital Operations & Process Optimization at GSK.

GSK’s ongoing commitment to producing research data of the highest quality has led them to emphasize trial solutions that enhance the patient experience. Science 37 had the capabilities to screen across most U.S. states, in many places where there were no brick-and-mortar sites participating. Additionally, Science 37 enabled participants at risk of dropping out from traditional brick-and-mortar sites to transition seamlessly to an at-home trial experience, enhancing engagement while maintaining study continuity. This strategy led to impressive results, with 82.3% completing Part A of the trial—the crucial milestone for evaluating the investigational drug's initial effects compared to placebo.

"Once again, Science 37 has demonstrated its unique ability to meet the needs of study sponsors confronted by the most challenging enrollment and study conduct conditions,” said Dr. Debra Weinstein, VP of Internal Medicine and Principal Investigator at Science 37. “The enhanced access of a decentralized approach becomes invaluable when sponsors are dealing with small patient populations that are widely dispersed across countries or even continents.”

For more information about Science 37’s enrollment solutions and its role in delivering qualified participants to clinical research studies such as the GSK PBC trial, please visit www.science37.com.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

About Science 37

Science 37 accelerates clinical research by expanding patient access to trials, leading to faster approvals and better health outcomes. Our Direct-to-Patient Site and Patient Recruitment solutions enable life sciences companies to reach beyond traditional means of conducting clinical research. To learn more, visit www.science37.com, or email science37@science37.com.

To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies.  

Media Inquiries

Science 37

pr@science37.com

Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Decentralized Clinical Trials

Top Honor Recognizes Science 37’s Visionary Innovation, Market-Leading Performance, and Unmatched Customer Care in the Decentralized Clinical Trials Industry

MORRISVILLE, NC — September 16, 2024 — Today, Science 37, a leader in enhancing patient access to clinical trials, announced that it has received Frost & Sullivan’s 2024 Global Company of the Year Award. Recognizing the market participant that exemplifies visionary innovation, market-leading performance, and unmatched customer care, the award solidifies Science 37’s growing influence in the clinical trial industry as it increasingly turns to decentralization to help overcome recruitment, enrollment, and retention challenges.

The internationally respected business consulting firm selected Science 37 after applying a rigorous analytical process that considered multiple nominees. A detailed evaluation of Best Practices criteria across two dimensions resulted in Science 37 earning the consultancy’s top honor in the decentralized clinical trials space. “Frost & Sullivan applauds Science 37 for its exemplary implementation of best practices driven by an excellent development strategy,” commented Valentina Barcia, Best Practices Research Analyst at Frost & Sullivan.

"We are deeply honored to receive Frost & Sullivan’s Best Practices Award," said David Coman, Chief Executive Officer at Science 37. "This recognition as the leader in decentralized clinical trials underscores the vision, dedication, and hard work of our entire team. We remain committed to transforming the clinical trial process to better serve patients and sponsors alike."

To learn more about Science 37 and its award-winning approach, read the full Frost & Sullivan report.

About Frost & Sullivan

 For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. For more information, visit www.frost.com.

About Science 37

Science 37’s mission is to accelerate clinical research by enabling universal trial access for patients. Through our solutions; the Direct-to-Patient Site and Patient Recruitment, we accelerate enrollment by expanding the reach of clinical trials to patients beyond the traditional site and rigorously qualifying patients prior to referring them to a traditional site. Our solutions are powered by a proprietary technology stack with in-house medical and operational experts that enhance quality through standardized workflows and best-in-class study orchestration. To learn more, visit www.science37.com, or email science37@science37.com.

To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies.

Media Inquiries

 Science 37

PR@science37.com

Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC

19,000-square-foot facility reflects the company’s recent growth and continued commitment to the region

MORRISVILLE, NC — August 6, 2024 — Science 37, a leader in enhancing patient access to clinical trials, today announced the grand opening of its new, 19,000-square-foot corporate headquarters in Morrisville, North Carolina, in the heart of Research Triangle Park.

The new, state-of-the-art facility, will serve as a hub for all Science 37 operations, enabling cross-functional teams with greater opportunities for collaborative problem-solving and integrated solution delivery. Centralizing operations in one facility will enable Science 37 to deliver patient recruitment and study conduct support on behalf of clinical trial sponsors with greater consistency, speed, and quality.

When asked about relocating to their new offices, Science 37 Chief Executive Officer, David Coman, stated, “Practically speaking, we’re better situated than ever to help our sponsors navigate the challenges of recruiting, enrolling, and treating difficult-to-reach patient populations. Symbolically, this move is just as important. It demonstrates our commitment to the region and to helping our sponsors improve their probability of success.”


To learn more about the Science 37, please visit www.science37.com.

About Science 37

Science 37’s mission is to accelerate clinical research by enabling universal trial access for patients. Through our solutions; the Direct-to-Patient Site and Patient Recruitment, we accelerate enrollment by expanding the reach of clinical trials to patients beyond the traditional site and rigorously qualifying patients prior to referring them to a traditional site. Our solutions are powered by a proprietary technology stack with in-house medical and operational experts that enhance quality through standardized workflows and best-in-class study orchestration. To learn more, visit www.science37.com, or email science37@science37.com.

To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies. 

Media Inquiries

Science 37
PR@science37.com